Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Advances in Systemic Treatment Options for Prurigo Nodularis
Author(s):
A panelist discusses how the treatment landscape for prurigo nodularis (PN) has evolved from primarily using topical therapies and off-label systemic medications to incorporating FDA-approved targeted biologics such as dupilumab and nemolizumab, which have demonstrated significant efficacy in reducing both the itchiness and nodular lesions.
Video content above is prompted by the following:
- Priorto the FDA approval of 2 systemic treatment options for PN, what was your typical treatment approach for patients with PN? At what point would systemic therapy be considered for a patient?
- How has this treatment approach changed in recent years after the FDA approval of biologic systemic treatments for PN? In your opinion, what is the role in therapy for these agents?
- Briefly discuss the 2 agents that are currently FDA-approved for PN, including how they work to address itch and skin lesions, as well as efficacy and safety data.
- Dupilumab
- Nemolizumab
- Discuss other systemic therapies in the pipeline for the treatment of prurigo nodularis (eg, Janus kinase inhibitors).
Related Videos
Related Content
